Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma (cHL) is a B-cell malignancy that, typically, responds well to standard therapies. However, patients who relapse after standard regimens or are refractory to induction therapy have a dismal outcome. The implementation of novel therapies such as the anti-CD30 monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Eleonora, d’Amore, Francesco, Carlo-Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862619/
https://www.ncbi.nlm.nih.gov/pubmed/31694167
http://dx.doi.org/10.3390/ijms20215503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862619/
https://www.ncbi.nlm.nih.gov/pubmed/31694167
http://dx.doi.org/10.3390/ijms20215503

Ejemplares similares